^
Association details:
| Biomarker: | KRAS exon 3 mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Vectibix (panitumumab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer
Published date:
09/04/2015
Excerpt:
We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective-retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) versus FOLFIRI alone as second-line therapy in patients with metastatic colorectal cancer...Outcomes were from the study's primary analysis. RAS mutations beyond KRAS exon 2 (KRAS exons 3, 4; NRAS exons 2, 3, 4; BRAF exon 15) were detected by bidirectional Sanger sequencing in wild-type KRAS exon 2 tumor specimens. Patients with RAS mutations were unlikely to benefit from panitumumab. Patients with RAS mutations were unlikely to benefit from panitumumab-FOLFIRI.
Secondary therapy:
FOLFIRI
DOI:
10.1158/1078-0432.CCR-15-0526
Trial ID:
Source:
Title:
Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer
Excerpt:
...- KRAS exon 3 (codons 59/61)...
Trial ID:
Source:
Title:
Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced RAS Wildtype Rectal Cancer (Clinical Stages II and III)
Excerpt:
...- KRAS exon 3 (codons 59/61)...
Trial ID:
More C2 evidence
Source:
Title:
Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery
Excerpt:
...Absence of mutations in KRAS (mutations in KRAS exon 2 [codons 12/13], exon 3 [codons 59/61] and exon 4 [codon 117/146], NRAS (NRAS exon 2 [codons 12/13], exon 3 [codons 59/61] and exon 4 [codons 117/146]), BRAF (exon 15 [codon 600] and PI3KCA in exons 9 and 20 7....
Trial ID:
Source:
Title:
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Excerpt:
...- KRAS exon 3 (codons 59/61)...
Trial ID:
Source:
Title:
FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)
Excerpt:
...- KRAS exon 3 (codons 59/61)...
Trial ID:
Source:
Title:
Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer
Excerpt:
...- Wild-type KRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) and wild-type NRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) tumor status....
Trial ID:
